Bernardus MacHielse
Direttore/Membro del Consiglio presso REDWOOD HOLDING S.A.
Profilo
Bernardus N.
M.
MacHielse is currently the Chairman at Polyneuron Pharmaceuticals AG, Director at Redwood Holding SA, and Director at F3 Platform Biologics, Inc. He previously held positions as President, Chief Executive Officer & Director at Vtesse, Inc., Director at Xencor, Inc., Director at AbCellera Boston, Inc., Quality Director at Janssen Biologics BV, Executive Vice President-Operations at MedImmune LLC, Vice President-Quality Assurance & Control at XOMA Corp., and Chief Operating Officer & Executive Vice President at Omthera Pharmaceuticals, Inc. He received his undergraduate and graduate degrees from the University of Utrecht.
Posizioni attive di Bernardus MacHielse
| Società | Posizione | Inizio |
|---|---|---|
| REDWOOD HOLDING S.A. | Direttore/Membro del Consiglio | 01/01/2018 |
F3 Platform Biologics, Inc.
 F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Direttore/Membro del Consiglio | - |
Polyneuron Pharmaceuticals AG
 Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Presidente | 01/01/2019 |
Precedenti posizioni note di Bernardus MacHielse
| Società | Posizione | Fine |
|---|---|---|
Omthera Pharmaceuticals, Inc.
 Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Direttore operativo | 01/08/2013 |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Amministratore Delegato | - |
Janssen Biologics BV
 Janssen Biologics BV Pharmaceuticals: MajorHealth Technology Janssen Biologics BV manufactures, acquires and markets biopharmaceutical therapies. The firms products focus on cardiovascular and immunological disorders, and cancer. The company was founded in 1984 and is headquartered in Leiden, the Netherlands. | Corporate Officer/Principal | - |
| XOMA CORPORATION | Corporate Officer/Principal | - |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Direttore/Membro del Consiglio | - |
Formazione di Bernardus MacHielse
| University of Utrecht | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| XENCOR, INC. | Health Technology |
| XOMA CORPORATION | Health Technology |
| Aziende private | 8 |
|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
AbCellera Boston, Inc.
AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Health Technology |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
Janssen Biologics BV
Janssen Biologics BV Pharmaceuticals: MajorHealth Technology Janssen Biologics BV manufactures, acquires and markets biopharmaceutical therapies. The firms products focus on cardiovascular and immunological disorders, and cancer. The company was founded in 1984 and is headquartered in Leiden, the Netherlands. | Health Technology |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Health Technology |
Polyneuron Pharmaceuticals AG
Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Redwood Holding SA
 Redwood Holding SA Metal FabricationProducer Manufacturing Redwood Holding SA engages in the manufacture and distribution of tools and equipment. Its products include bearings, screws, toothed wheels and gears, and components. The company was founded by Michal Tomasz Nowacki in 1993 and is headquartered in Lodz, Poland.^ | Producer Manufacturing |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
- Borsa valori
- Insiders
- Bernardus MacHielse
